EpiVax Inc - Strategic SWOT Analysis Review

GlobalData
30 Pages - GLDATA61376
$125.00

EpiVax Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – GlobalData’s summarization of the company’s business strategy.
- SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.

Highlights

EpiVax Inc (EpiVax) is an immunology company which develops analytical capabilities in the field of computational immunology. Its product pipeline includes Tregitopes; deimmunization projects including deimmunized botox and deimmunized FVIII; and biodefense vaccines. Tregitopes are linear sequences of amino acids which activate natural regulatory T cells. It is an immune-modulation power tool being developed for auto-immune, auto-inflammatory and allergic conditions. EpiVax’ service portfolio includes, immune engineering, immunogenicity screening, vaccine design and redesign. It also provides lab services such as in vivo, in vitro and ex vivo immunogenicity screening services including cell-free HLA binding assays. EpiVax is headquartered in Providence, Rhode Island, the US.

EpiVax Inc Key Recent Developments

Sep 06, 2016: EpiVax to Advance Development of Vaccine Against Stealth Flu Virus with New NIH-SBIR Funding
Jan 11, 2016: EpiVax spins out Aceno Biotherapeutics at JP Morgan/Biotech Showcase 2016

Reasons to Buy

- Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
- Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
- Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.

'

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Section 1 - About the Company 5
EpiVax Inc - Key Facts 5
EpiVax Inc - Key Employees 6
EpiVax Inc - Key Employee Biographies 7
EpiVax Inc - Key Operational Employees 8
EpiVax Inc - Major Products and Services 9
EpiVax Inc - Pharmaceutical Pipeline Products Data 10
EpiVax Inc, Pipeline Products by Therapy Area 10
EpiVax Inc, Pipeline Products by Development Phase 11
EpiVax Inc - History 12
EpiVax Inc - Company Statement 16
EpiVax Inc - Locations And Subsidiaries 17
Head Office 17
Section 2 – Company Analysis 18
EpiVax Inc - Business Description 18
EpiVax Inc - Corporate Strategy 19
EpiVax Inc - SWOT Analysis 20
SWOT Analysis - Overview 20
EpiVax Inc - Strengths 20
EpiVax Inc - Weaknesses 21
EpiVax Inc - Opportunities 22
EpiVax Inc - Threats 23
EpiVax Inc - Key Competitors 24
Section 3 – Company’s Lifesciences Financial Deals and Alliances 25
EpiVax Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 25
EpiVax Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 26
EpiVax Inc, Recent Deals Summary 27
Section 4 – Company’s Recent Developments 28
Sep 06, 2016: EpiVax to Advance Development of Vaccine Against Stealth Flu Virus with New NIH-SBIR Funding 28
Jan 11, 2016: EpiVax spins out Aceno Biotherapeutics at JP Morgan/Biotech Showcase 2016 29
Section 5 – Appendix 30
Methodology 30
About GlobalData 30
Contact Us 30
Disclaimer 30

List of Tables
EpiVax Inc, Key Facts 5
EpiVax Inc, Key Employees 6
EpiVax Inc, Key Employee Biographies 7
EpiVax Inc, Key Operational Employees 8
EpiVax Inc, Major Products and Services 9
EpiVax Inc, Number of Pipeline Products by Therapy Area 10
EpiVax Inc, Number of Pipeline Products by Development Stage 11
EpiVax Inc, History 12
EpiVax Inc, Key Competitors 24
EpiVax Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 25
EpiVax Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 26
EpiVax Inc, Recent Deals Summary 27

List of Figures
EpiVax Inc, Pipeline Products by Therapy Area 10
EpiVax Inc, Pipeline Products by Development Phase 11
EpiVax Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 25
EpiVax Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 26

$125.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

Please contact us at [email protected]
or +1 212 564 2838

 

Custom Research

Contact us to speak
with your industry analyst.

[email protected] 
+1 212 564 2838

 



Discount Codes

Request Discount Codes
for reports of interest to you.

[email protected]
+1 212 564 2838